Abstract:Aims Current understanding of the prognosis for patients with chronic kidney disease (CKD) and overlapping cardio‐renal‐metabolic components, specifically heart failure (HF) and diabetes mellitus (DM), remains limited. While previous studies have explored the interactions between CKD, HF, and DM, they have predominantly focused on cohorts of HF or DM patients. This study aims to fill this gap by investigating the long‐term outcomes and treatment patterns in a cohort of CKD patients, particularly those with coexisting HF and DM. Methods and results We analysed data from the Swedish national CKD patient cohort, the Swedish Renal Registry, with a follow‐up period extending up to 10 years. The study examined the risks of all‐cause mortality, major adverse cardiovascular events (MACE)—defined as a composite of non‐fatal myocardial infarction, hospitalization for congestive HF, non‐fatal stroke, or cardiovascular death—and the initiation of kidney replacement therapy (KRT). Analyses were conducted using Cox proportional hazards and competing risk models. Among the 27 647 patients, 48% had CKD alone, 12% had CKD with HF, 27% had CKD with DM, and 13% had CKD with both HF and DM. After 5 years, mortality rates were 23% for patients with CKD, 30% for those with CKD/DM, 54% for CKD/HF, and 55% for CKD/HF/DM. The 10 year absolute risk of MACE was 28% for CKD alone, 35% for CKD/DM, 67% for CKD/HF, and 73% for CKD/HF/DM. The adjusted hazard ratio (HR) for mortality was approximately three times higher in patients with any HF combination, with HRs of 2.57 [95% confidence interval (CI) 2.43–2.71] for CKD/HF and 3.22 (95% CI 3.05–3.39) for CKD/HF/DM, compared with CKD alone. The impact of HF on MACE prognosis was even more pronounced, with adjusted sub‐hazard ratios (SHRs) of 3.33 (95% CI 3.14–3.53) for CKD/HF and 4.26 (95% CI 4.04–4.50) for CKD/HF/DM. Additionally, CKD patients diagnosed with HF were less likely to commence KRT, and the risk of death prior to KRT initiation was roughly twice as high for these groups, with SHRs of 2.05 (95% CI 1.93–2.18) for CKD + HF and 2.43 (95% CI 2.29–2.58) for CKD + HF + DM. Conclusions In a cohort of CKD patients, having HF contributes substantially to increased mortality and the risk of MACE, and these patients are less likely to start KRT. These findings highlight the urgent need for targeted therapeutic strategies and management plans for CKD patients, particularly those with concurrent HF, to enhance patient prognosis.

Heart failure with reduced ejection fraction and chronic kidney disease: a focus on therapies and interventions

An Updated Review of the Management of Chronic Heart Failure in Patients with Chronic Kidney Disease

Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease

The Treatment of Heart Failure in Patients with Chronic Kidney Disease: Doubts and New Developments from the Last ESC Guidelines

Management of patients with heart failure and chronic kidney disease

Management of Heart Failure in Patients with Chronic Kidney Disease

Heart failure management in dialysis patients: Many treatment options with no clear evidence

Pathophysiological Link and Treatment Implication of Heart Failure and Preserved Ejection Fraction in Patients with Chronic Kidney Disease

Chronic Kidney Disease as a Risk Factor for Heart Failure With Preserved Ejection Fraction: A Focus on Microcirculatory Factors and Therapeutic Targets

What to do with foundation therapies for heart failure for patients with end-stage kidney disease on haemodialysis

Interrelation between heart failure with preserved ejection fraction and renal impairment

Representation of Chronic Kidney Disease in Randomized Controlled Trials Among Patients With Heart failure With Reduced Ejection Fraction: A Systematic Review

Heart failure and kidney dysfunction: epidemiology, mechanisms and management

Epidemiology and Management of Patients With Kidney Disease and Heart Failure With Preserved Ejection Fraction

Kidney Replacement Therapies in Advanced Heart Failure – Timing, Modalities, and Clinical Considerations

Implantable Cardioverter Defibrillator and Resynchronization Therapy in Patients With Overt Chronic Kidney Disease: JACC State-of-the-Art Review

Heart Failure With Preserved Ejection Fraction With CKD: A Narrative Review of a Multispecialty Disorder

Heart Failure in Patients with Diabetes and Chronic Kidney Disease: Challenges and Opportunities

Risk Factors and Outcomes Associated With Heart Failure With Preserved and Reduced Ejection Fraction in People With Chronic Kidney Disease

Use of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence

Heart failure: the grim reaper of the cardio‐renal‐metabolic triad